These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6312914)

  • 21. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males.
    Clay PG; Graham MR; Lindsey CC; Lamp KC; Freeman C; Glaros A
    Am J Geriatr Pharmacother; 2004 Sep; 2(3):181-9. PubMed ID: 15561650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative clinical evaluation of ceftriaxone in treating lower respiratory tract infections.
    Abbate GF; Alagia I; Giaquinto E; Leonessa V; Caputi M; Guarino C; Micillo E; Catena E; Altucci P
    Chemioterapia; 1986 Feb; 5(1):26-32. PubMed ID: 3955779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outpatient use of ceftriaxone: a cost-benefit analysis.
    Poretz DM; Woolard D; Eron LJ; Goldenberg RI; Rising J; Sparks S
    Am J Med; 1984 Oct; 77(4C):77-83. PubMed ID: 6093525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program.
    Williams DN; Bosch D; Boots J; Schneider J
    Clin Ther; 1993; 15(1):169-79; discussion 168. PubMed ID: 8458046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormal laboratory test values during ceftriaxone therapy.
    Oakes M; MacDonald H; Wilson D
    Am J Med; 1984 Oct; 77(4C):89-96. PubMed ID: 6093527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings.
    Eron LJ; Park CH; Hixon DL; Goldenberg RI; Poretz DM
    Antimicrob Agents Chemother; 1983 May; 23(5):731-7. PubMed ID: 6307135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ceftriaxone, a long-acting cephalosporin. Microbiological, kinetic and clinical study].
    Soranzo ML; Capra E; Angela GC; Eandi M; Salassa B; Lollini P; Musso E; Pizzo L; Spezia C; Di Nola F
    Minerva Med; 1983 Sep; 74(36):2093-102. PubMed ID: 6312379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative experimental antibacterial activity of ceftriaxone (Ro 13-9904).
    Böhni E
    Chemioterapia; 1984 Feb; 3(1):25-32. PubMed ID: 6100173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftriaxone: therapeutic results in various infections and kinetic studies.
    Giamarellou HJ; Tsagarakis J; Petrikkos G; Mavroudis K; Veldekis D; Daikos GK
    Arzneimittelforschung; 1984; 34(3):321-5. PubMed ID: 6329238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of ceftriaxone in ambulatory patients.
    Raz R; Kennes Y
    Chemioterapia; 1988 Jun; 7(3):169-72. PubMed ID: 3168071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.
    Paganini H; Gómez S; Ruvinsky S; Zubizarreta P; Latella A; Fraquelli L; Iturres AS; Casimir L; Debbag R
    Cancer; 2003 Apr; 97(7):1775-80. PubMed ID: 12655535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit.
    Girmenia C; Alimena G; Latagliata R; Morano SG; Celesti F; Coppola L; Spadea A; Tosti S; Mecarocci S; D'Elia GM; Tafuri A; Cimino G; Mandelli F
    Haematologica; 1999 Sep; 84(9):814-9. PubMed ID: 10477455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia].
    García-Contreras F; Del-Angel-García G; Ramírez Cuenca A; Malváez-Valdes M; Vega Yáñez A; Amato D
    Rev Invest Clin; 2000; 52(4):418-26. PubMed ID: 11061104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiologic and clinical studies with cefuroxime.
    Graber H; Arr M; Magyar T; Ludwig E
    Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):399-403. PubMed ID: 6629544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.
    Sàbat M; Kolle L; Soriano G; Ortiz J; Pamplona J; Novella MT; Villanueva C; Sainz S; Torras J; Balanzó J; Guarner C
    Am J Gastroenterol; 1998 Dec; 93(12):2457-62. PubMed ID: 9860409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Martínez Jabaloyas JM; Sanz Chinesta S; Jiménez Cruz JF; Flores Corral N; Unda Urzaiz M; Leiva Galvis O; González Romojaro V; Hernández Fernández C; Lledó García E; Rioja Sanz LA; Gonzalvo Ibarra A; Camacho González JE; Ruíz Alvárez-Cienfuegos F; Resel Estévez L; Corral Saleta J; Burgos Rodríguez R; Del Rosal Samaniego JM
    Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.